Humedix Co Ltd (200670) - Net Assets
Based on the latest financial reports, Humedix Co Ltd (200670) has net assets worth ₩265.23 Billion KRW (≈ $179.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩288.63 Billion ≈ $195.60 Million USD) and total liabilities (₩23.40 Billion ≈ $15.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Humedix Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩265.23 Billion |
| % of Total Assets | 91.89% |
| Annual Growth Rate | 8.48% |
| 5-Year Change | 90.34% |
| 10-Year Change | N/A |
| Growth Volatility | 12.89 |
Humedix Co Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Humedix Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 200670 total assets for the complete picture of this company's asset base.
Annual Net Assets for Humedix Co Ltd (2015–2024)
The table below shows the annual net assets of Humedix Co Ltd from 2015 to 2024. For live valuation and market cap data, see Humedix Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩228.53 Billion ≈ $154.87 Million |
+15.38% |
| 2023-12-31 | ₩198.06 Billion ≈ $134.22 Million |
+42.38% |
| 2022-12-31 | ₩139.11 Billion ≈ $94.27 Million |
+10.41% |
| 2021-12-31 | ₩125.99 Billion ≈ $85.38 Million |
+4.93% |
| 2020-12-31 | ₩120.07 Billion ≈ $81.37 Million |
+7.10% |
| 2019-12-31 | ₩112.10 Billion ≈ $75.97 Million |
+5.62% |
| 2018-12-31 | ₩106.13 Billion ≈ $71.93 Million |
-1.65% |
| 2017-12-31 | ₩107.92 Billion ≈ $73.13 Million |
-1.09% |
| 2016-12-31 | ₩109.11 Billion ≈ $73.94 Million |
-0.63% |
| 2015-12-31 | ₩109.80 Billion ≈ $74.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Humedix Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 473.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩131.11 Billion | 57.37% |
| Common Stock | ₩5.61 Billion | 2.46% |
| Other Components | ₩91.81 Billion | 40.17% |
| Total Equity | ₩228.53 Billion | 100.00% |
Humedix Co Ltd Competitors by Market Cap
The table below lists competitors of Humedix Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kogan.com Ltd
AU:KGN
|
$246.49 Million |
|
Profound Medical Corp
TO:PRN
|
$246.52 Million |
|
SIM Acquisition Corp. I Class A Ordinary Shares
NASDAQ:SIMA
|
$246.56 Million |
|
Polyram Plastic Industries Ltd
TA:POLP
|
$246.74 Million |
|
Metro Mining Limited
F:6ME
|
$246.37 Million |
|
Luca Mining Corp.
V:LUCA
|
$246.28 Million |
|
CERRO DE PASCO RES
F:N8HP
|
$246.28 Million |
|
Shandong Longertek Technology Co Ltd
SHE:300594
|
$246.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Humedix Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 198,063,056,240 to 228,532,467,360, a change of 30,469,411,120 (15.4%).
- Net income of 39,259,414,550 contributed positively to equity growth.
- Dividend payments of 5,950,044,400 reduced retained earnings.
- Share repurchases of 2,838,501,700 reduced equity.
- New share issuances of 157,597,800 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩39.26 Billion | +17.18% |
| Dividends Paid | ₩5.95 Billion | -2.6% |
| Share Repurchases | ₩2.84 Billion | -1.24% |
| Share Issuances | ₩157.60 Million | +0.07% |
| Other Changes | ₩-159.06 Million | -0.07% |
| Total Change | ₩- | 15.38% |
Book Value vs Market Value Analysis
This analysis compares Humedix Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.19x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩11097.48 | ₩35350.00 | x |
| 2017-12-31 | ₩11176.84 | ₩35350.00 | x |
| 2018-12-31 | ₩11137.12 | ₩35350.00 | x |
| 2019-12-31 | ₩11769.60 | ₩35350.00 | x |
| 2020-12-31 | ₩12768.22 | ₩35350.00 | x |
| 2021-12-31 | ₩13398.53 | ₩35350.00 | x |
| 2022-12-31 | ₩15205.30 | ₩35350.00 | x |
| 2023-12-31 | ₩19053.67 | ₩35350.00 | x |
| 2024-12-31 | ₩22168.85 | ₩35350.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Humedix Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.18%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.25%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.09x
- Recent ROE (17.18%) is above the historical average (11.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 10.59% | 27.59% | 0.36x | 1.06x | ₩642.36 Million |
| 2016 | 9.42% | 21.80% | 0.36x | 1.20x | ₩-636.30 Million |
| 2017 | 11.06% | 21.82% | 0.42x | 1.20x | ₩1.15 Billion |
| 2018 | 8.68% | 14.20% | 0.51x | 1.21x | ₩-1.41 Billion |
| 2019 | 9.30% | 13.25% | 0.57x | 1.23x | ₩-790.13 Million |
| 2020 | 12.56% | 15.32% | 0.56x | 1.46x | ₩3.08 Billion |
| 2021 | 7.19% | 8.17% | 0.51x | 1.71x | ₩-3.53 Billion |
| 2022 | 15.16% | 17.12% | 0.54x | 1.63x | ₩7.18 Billion |
| 2023 | 12.53% | 16.30% | 0.69x | 1.11x | ₩5.01 Billion |
| 2024 | 17.18% | 24.25% | 0.65x | 1.09x | ₩16.41 Billion |
Industry Comparison
This section compares Humedix Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $417,135,058,503
- Average return on equity (ROE) among peers: 2.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Humedix Co Ltd (200670) | ₩265.23 Billion | 10.59% | 0.09x | $246.43 Million |
| Dongwha Pharm.Co.Ltd (000020) | $296.94 Billion | 15.83% | 0.24x | $113.83 Million |
| Yuhan Corp. (000100) | $756.45 Billion | 11.87% | 0.32x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.61 Trillion | 6.79% | 0.30x | $59.61 Million |
| Yuyu Pharma (000220) | $73.73 Billion | -0.34% | 0.41x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $123.37 Billion | -4.85% | 0.58x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $71.49 Billion | -10.45% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $164.95 Billion | -2.25% | 0.61x | $76.14 Million |
| Samil Pharm (000520) | $65.75 Billion | -8.13% | 2.44x | $127.90 Million |
| Donga Socio Holdings (000640) | $746.90 Billion | 2.65% | 0.82x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Humedix Co Ltd
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more